PT-141 acts on the brain, not the blood vessels — here is the safety record the trials actually measured.

The short version

PT-141 is a lab name for bremelanotide. It is a small peptide — a short chain of amino acids — that switches on a brain receptor called MC4R (a docking site in the hypothalamus that helps control sexual desire and appetite). Most arousal drugs work on blood flow. This one works on the brain's wiring for wanting ^[1].

The US drug regulator approved one version, an injection, for premenopausal women with low sexual desire that causes distress ^[7]. That is the only approved use. Use in men, in postmenopausal women, or for "performance" is off-label or still experimental — the studies in those groups are smaller and not the basis for approval ^[7].

In the women's trials the desire scores went up a little and held steady over a year ^[3][4]. The main downside was nausea — roughly four in ten people over long-term use felt sick ^[4]. It can also nudge blood pressure up for a short time, so the label warns against it in uncontrolled high blood pressure ^[7]. What people report, including the downsides, is on the PT-141 effects page.

The material sold online as a "research chemical" is not the approved drug and is not quality-controlled ^[12].

What is PT-141

PT-141 is a synthetic cyclic heptapeptide — seven amino acids joined in a ring — modelled on alpha-MSH (alpha-melanocyte-stimulating hormone), a natural brain signalling molecule ^[1]. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH; molecular weight 1025.2 Da. The ring (a lactam bridge between two side chains) makes it more stable than a straight-chain peptide.

The PT-141 peptide is an agonist — a switch-on key — at the melanocortin receptors MC3R and MC4R, which sit mainly in the central nervous system ^[1]. The international nonproprietary name is bremelanotide. It is a structural relative of melanotan II, but built for sexual-desire signalling rather than skin pigmentation.

Mechanism is central, not vascular. In rats and nonhuman primates, systemic dosing produced erections and lit up hypothalamic neurons (a marker called c-Fos rose) — a brain effect, not a blood-flow one ^[1]. It is not a PDE-5 inhibitor and does not act on vascular smooth muscle ^[7].

What the trials found

Two identical Phase 3 trials, run as one program called RECONNECT, enrolled 1,267 premenopausal women with hypoactive sexual desire disorder (HSDD — persistent low desire that causes distress) ^[3]. The injection produced a statistically significant rise in sexual desire (integrated FSFI-desire +0.35, P<.001) and a drop in desire-related distress (integrated FSDS-DAO item 13 −0.33, P<.001) versus placebo over 24 weeks ^[3].

A 52-week open-label extension followed 684 women. No new safety signals appeared and the desire gains held ^[4]. A neuroimaging study (n=31) showed MC4R agonism raised desire for up to 24 hours and changed how the brain processed erotic cues — enhanced amygdala-insula connectivity ^[5].

The effect sizes are real but small. A critical meta-analysis of female-sexual-dysfunction trials found placebo accounted for about 67.7% of the measured effect ^[13]. The numbers are precise; the clinical magnitude is debated ^[9].

Where the numbers point

Terminal half-life is approximately 2.7 hours (range 1.9–4.0 h) after subcutaneous injection ^[7]. The full pharmacokinetic constants are on the PT-141 half life page. The adverse-event rates — nausea, flushing, headache, the blood-pressure warning, hyperpigmentation — sit on PT-141 effects. The dose context, framed as studied doses and the approved label, is on PT-141 research and the dosage page.

What is settled: a central MC4R mechanism, a measured PK profile, a defined adverse-event set ^[1][7]. What is open: every use outside premenopausal-women HSDD, the clinical meaningfulness of the desire gains, and any signal from unregulated "research chemical" supply ^[9][12].